Abstract Body

Background: New agents for HCV treatment have dramatically improved both ease and success of treatment intervention. It is imperative that healthcare providers managing HCV understand key concepts in the staging of liver disease, and critical management considerations.Staging of liver disease to determine if advanced fibrosis or cirrhosis is present remains important. Cirrhosis is associated with poorer treatment outcomes and increased risk of hepatic decompensation and liver cancer. A variety of modalities are now available for staging of liver disease including non-invasive measures such as transient elastography and biomarker algorithms. Liver biopsy may still play a role in a limited proportion of patients. Determination of advanced fibrosis/cirrhosis mandates enrollment in hepatocellular carcinoma (HCC) surveillance and evaluation of esophageal varices. Careful assessment is needed in the setting of cirrhosis to determine liver transplant candidacy prior to treatment intervention. Conclusions: HCV healthcare providers should be familiar with the process of fibrosis staging, and appropriately identify patients who would benefit from surveillance for HCC and esophageal varices. Hepatic decompensation recognition is critical and should lead to rapid consultation with a liver transplant specialist.